- NCIt
- C4628
Loading cancer entity…
Loading cancer entity…
Clinical trials
107 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07833657 | Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases(ITST-ADC-LM) | not yet recruiting | Phase 2 | 28 | Jiuda ZhaoOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07778940 | Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.(LEP-THP-2026) | not yet recruiting | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER |
| 1 |
| Aug 21, 2026 |
| clinicaltrials |
| NCT07414979 | Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma | not yet recruiting | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07702305 | Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer | not yet recruiting | Phase 1 | 15 | Henan Cancer HospitalOTHER_GOV | 0 | Jul 14, 2026 | clinicaltrials |
| NCT07674693 | Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases | not yet recruiting | Phase 1 | 29 | NYU Langone HealthOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT07551414 | Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI | not yet recruiting | Phase 2 | 38 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07172178 | γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma | not yet recruiting | Early Phase 1 | 12 | Nanjing Medical UniversityOTHER | 0 | Sep 15, 2025 | clinicaltrials |
| NCT06971406 | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis(FLAME-1) | not yet recruiting | Phase 2 | 100 | Qiming WangOTHER_GOV | 0 | May 14, 2025 | clinicaltrials |
| NCT06861218 | Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases | not yet recruiting | Phase 2 | 42 | Zhejiang Cancer HospitalOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06766591 | Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs | not yet recruiting | N/A | 36 | Jiangsu Province Nanjing Brain HospitalOTHER | 0 | Jan 9, 2025 | clinicaltrials |
| NCT06441045 | Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI | not yet recruiting | Phase 2 | 112 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 4, 2024 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials